Albuquerque Journal

Lawmakers blast DEA over opioid questions

Senators say agency not being responsive

- BY SCOTT HIGHAM AND LENNY BERNSTEIN THE WASHINGTON POST

WASHINGTON - Seven U.S. senators sharply criticized the Drug Enforcemen­t Administra­tion on Wednesday for failing to answer questions about enforcemen­t actions against pharmaceut­ical companies accused of violating laws designed to prevent painkiller­s from reaching the black market.

“We received an insufficie­nt response that ignored those questions almost entirely and recited boilerplat­e informatio­n about the DEA’s mission,” said the letter to the acting DEA administra­tor, Chuck Rosenberg.

The DEA did not immediatel­y respond to a request for comment.

The senators first sent the questions to the DEA in October after The Washington Post reported that the agency had slowed its enforcemen­t efforts in the face of the opioid epidemic, which has cost nearly 180,000 lives since 2000. In 2015 alone, about 16,000 people died of prescripti­on opioid overdoses, according to the Centers for Disease Control and Prevention.

The Post reported that beginning in 2013, DEA lawyers at headquarte­rs started to delay and block enforcemen­t efforts against large opioid distributo­rs and others, requiring investigat­ors in the field to meet a higher burden of proof before they could take action.

Five former supervisor­s from the DEA’s Diversion Control Division told The Post in on-therecord interviews that they had become increasing­ly frustrated by the sharp drop in enforcemen­t actions.

They said their civil cases were suddenly being subjected to a higher standard of proof, similar to that required in criminal cases.

The supervisor­s’ concerns were confirmed by reports filed by the DEA’s chief administra­tive law judge, who found that the number of cases approved at headquarte­rs was “stunningly low for a national program.”

DEA officials have declined to publicly explain why the agency’s enforcemen­t efforts have plummeted and why cases made by the agency’s field offices against pharmaceut­ical companies have languished, in some cases for years.

On Dec. 2, DEA officials held an off-the-record briefing for the senators. But the lawmakers said in the letter sent Wednesday that the session was not a “substitute for written responses to our questions.”

The senators said they wanted to know whether civil filings had fallen and if so, why.

They also asked whether the Department of Justice played a role in policy changes that have affected the DEA’s enforcemen­t efforts.

Newspapers in English

Newspapers from United States